CRYO-CELL International is engaged in cryogenic cellular storage and the design and developmentof cellular storage devices. They currently focus on the processing and preservation of umbilical cord blood stem cells for autologous/sibling use. They have pioneered several technologies that allow for the processing and storage of specimens in a cryogenic environment, and presently, their mission of affordability for U-Cord blood preservation remains in effect.
| Revenue (Most Recent Fiscal Year) | $31.99M |
| Net Income (Most Recent Fiscal Year) | $0.40M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 510.00 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.28 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 28.45 |
| Pre-Tax Margin (Trailing 12 Months) | 7.92% |
| Net Margin (Trailing 12 Months) | 0.40% |
| Return on Equity (Trailing 12 Months) | -1.07% |
| Return on Assets (Trailing 12 Months) | 0.20% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.58 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.54 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 11.13 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-1.64 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $0.01 |
| Exchange | NYSEMKT |
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| Common Shares Outstanding | 8.08M |
| Free Float | 5.10M |
| Market Capitalization | $41.22M |
| Average Volume (Last 20 Days) | 9577.80 |
| Beta (Past 60 Months) | 0.71 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 36.86% |
| Percentage Held By Institutions (Latest 13F Reports) | 10.44% |
| Annual Dividend (Based on Last Quarter) | $0.60 |
| Dividend Yield (Based on Last Quarter) | 11.77% |